{"altmetric_id":4738718,"counts":{"readers":{"mendeley":12,"citeulike":0,"connotea":0},"total":{"posts_count":36},"news":{"unique_users_count":3,"unique_users":["drug_discovery_and_development","healio_com","eurekalert"],"posts_count":3},"blogs":{"unique_users_count":1,"unique_users":[369],"posts_count":1},"twitter":{"unique_users_count":20,"unique_users":["JAMA_current","HealMyHeartLA","JAMACardio","swarsabelle","medicineupdate","CitelineJakeM","gerrit_brand","AMAManual","acafarmur","DitchDocRN14","chemafraile","catambuco","TheKancerFound","ernestocardio","medvox","rabonaldi","annalsthorsurg","CardioPharmUK","JavaClinical","L_Borgese"],"posts_count":26},"facebook":{"unique_users_count":2,"unique_users":["87087958340","1648414928738217"],"posts_count":6}},"selected_quotes":["Further clinical trials of vericiguat needed to determine potential role for pts w worsening chronic HF","#Vericiguat and worsening #chronicheartfailure? #AHA15","What's the optimal dose, tolerability of vericiguat in ps w worsening #CHF w reduced LVEF?","Color can be useful in figures with many distinct data curves. From JAMA"],"citation":{"abstract":"Worsening chronic heart failure (HF) is a major public health problem.\nTo determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic HF and reduced left ventricular ejection fraction (LVEF).\nDose-finding phase 2 study that randomized 456 patients across Europe, North America, and Asia between November 2013 and January 2015, with follow-up ending June 2015. Patients were clinically stable with LVEF less than 45% within 4 weeks of a worsening chronic HF event, defined as worsening signs and symptoms of congestion and elevated natriuretic peptide level requiring hospitalization or outpatient intravenous diuretic.\nPlacebo (n\u2009=\u200992) or 1 of 4 daily target doses of oral vericiguat (1.25 mg [n\u2009=\u200991], 2.5 mg [n\u2009=\u200991], 5 mg [n\u2009=\u200991], 10 mg [n\u2009=\u200991]) for 12 weeks.\nThe primary end point was change from baseline to week 12 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point.\nOverall, 351 patients (77.0%) completed treatment with the study drug with valid 12-week NT-proBNP levels and no major protocol deviation and were eligible for primary end point evaluation. In primary analysis, change in log-transformed NT-proBNP levels from baseline to week 12 was not significantly different between the pooled vericiguat group (log-transformed: baseline, 7.969; 12 weeks, 7.567; difference, -0.402; geometric means: baseline, 2890 pg\/mL; 12 weeks, 1932 pg\/mL) and placebo (log-transformed: baseline, 8.283; 12 weeks, 8.002; difference, -0.280; geometric means: baseline, 3955 pg\/mL; 12 weeks, 2988 pg\/mL) (difference of means, -0.122; 90% CI, -0.32 to 0.07; ratio of geometric means, 0.885, 90% CI, 0.73-1.08; P\u2009=\u2009.15). The exploratory secondary analysis suggested a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level (P\u2009<\u2009.02). Rates of any adverse event were 77.2% and 71.4% among the placebo and 10-mg vericiguat groups, respectively.\nAmong patients with worsening chronic HF and reduced LVEF, compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerated. Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF.\nclinicaltrials.gov Identifier: NCT01951625.","altmetric_jid":"4f6fa4ee3cf058f610002c38","authors":["Mihai Gheorghiade","Stephen J. Greene","Javed Butler","Gerasimos Filippatos","Carolyn S. P. Lam","Aldo P. Maggioni","Piotr Ponikowski","Sanjiv J. Shah","Scott D. Solomon","Elisabeth Kraigher-Krainer","Eliana T. Samano","Katharina M\u00fcller","Lothar Roessig","Burkert Pieske"," ","Gheorghiade, Mihai","Greene, Stephen J","Butler, Javed","Filippatos, Gerasimos","Lam, Carolyn S P","Maggioni, Aldo P","Ponikowski, Piotr","Shah, Sanjiv J","Solomon, Scott D","Kraigher-Krainer, Elisabeth","Samano, Eliana T","M\u00fcller, Katharina","Roessig, Lothar","Pieske, Burkert",", "],"doi":"10.1001\/jama.2015.15734","first_seen_on":"2015-11-08T21:00:21+00:00","funders":["niehs"],"issns":["1538-3598","0098-7484"],"issue":"21","journal":"JAMA: Journal of the American Medical Association","last_mentioned_on":1452012603,"links":["http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195&utm_source=TWITTER&utm_medium=social_jn&utm_term=270992600&utm_content=%7Carticle_engagement&utm_campaign=article_alert&linkId=18533800","http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26547357?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195#.VkHDnJ-FJ5w.twitter","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195&utm_source=TWITTER&utm_medium=social_jn&utm_term=270992699&utm_content=article_promotion%7Carticle_engagement&utm_campaign=article_alert&linkId=18533045","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195&utm_source=TWITTER&utm_medium=social_jn&utm_term=270992699&utm_content=article_promotion|article_engagement&utm_campaign=article_alert&linkId=18533045","http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734&utm_source=TWITTER&utm_medium=social_jn&utm_term=270992699&utm_content=article_promotion%7Carticle_engagement&utm_campaign=article_alert&linkId=18533045","http:\/\/dx.doi.org\/10.1001\/jama.2015.15734","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195#.VmCxm2coxVw.twitter","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195&utm_source=TWITTER&utm_medium=social_jn&utm_term=282245199&utm_content=%7Carticle_engagement&utm_campaign=article_alert&linkId=18880256","http:\/\/jama.jamanetwork.com\/article.aspx?articleid=2469195#.VmXLuOq-7Og.twitter","http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734&utm_source=FBPAGE&utm_medium=social_jn&utm_term=270987991&utm_content=content_engagement%7Carticle_engagement&utm_campaign=article_alert&linkId=18532520","http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734&utm_source=FBPAGE&utm_medium=social_jn&utm_term=282243857&utm_content=content_engagement%7Carticle_engagement&utm_campaign=article_alert&linkId=18880262","http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734&utm_source=FBPAGE&utm_medium=social_jn&utm_term=270987897&utm_content=content_engagement%7Carticle_engagement&utm_campaign=article_alert&linkId=18561551"],"pdf_url":"http:\/\/jama.jamanetwork.com\/data\/Journals\/JAMA\/0\/joi150144.pdf","pmid":"26547357","pubdate":"2015-11-08T00:00:00+00:00","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"2251","subjects":["medicine"],"title":"Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial","type":"article","uri":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2015.15734","volume":"314","mendeley_url":"http:\/\/www.mendeley.com\/research\/effect-vericiguat-soluble-guanylate-cyclase-stimulator-natriuretic-peptide-levels-patients-worsening-8"},"altmetric_score":{"score":47.4,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":47.4},"context_for_score":{"all":{"total_number_of_other_articles":8016592,"mean":6.7761052824031,"rank":180334,"this_scored_higher_than_pct":97,"this_scored_higher_than":7836709,"rank_type":"exact","sample_size":8016592,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":245949,"mean":9.6346090230456,"rank":9790,"this_scored_higher_than_pct":96,"this_scored_higher_than":236151,"rank_type":"exact","sample_size":245949,"percentile":96},"this_journal":{"total_number_of_other_articles":19623,"mean":35.613148608705,"rank":2862,"this_scored_higher_than_pct":85,"this_scored_higher_than":16762,"rank_type":"exact","sample_size":19623,"percentile":85},"similar_age_this_journal_3m":{"total_number_of_other_articles":373,"mean":84.314005376344,"rank":141,"this_scored_higher_than_pct":62,"this_scored_higher_than":232,"rank_type":"exact","sample_size":373,"percentile":62}}},"demographics":{"poster_types":{"member_of_the_public":13,"researcher":1,"practitioner":4,"science_communicator":2},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":4,"Members of the public":13,"Science communicators (journalists, bloggers, editors)":2,"Scientists":1}},"mendeley":{"by_status":{"Researcher":2,"Student  > Ph. D. Student":5,"Student  > Postgraduate":1,"Student  > Master":1,"Other":2,"Professor":1},"by_discipline":{"Medicine and Dentistry":9,"Unspecified":2,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"US":6,"DE":1,"VE":1,"CL":1,"GB":1,"IE":1}}},"posts":{"news":[{"title":"Examining Optimal Dosage for Heart Failure Drug","url":"http:\/\/ct.moreover.com\/?a=23626273018&p=1pl&v=1&x=_-9MS5la2fGLlGCzHOOP3Q","license":"public","citation_ids":[4738718],"posted_on":"2015-12-04T15:03:45+00:00","summary":"A clinical trial led by Northwestern Medicine scientist Mihai Gheorghiade, MD, has shown that higher doses of the drug vericiguat may improve outcomes for patients with worsening chronic heart failure.","author":{"name":"Drug Discovery and Development ","url":"http:\/\/www.dddmag.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/228\/normal\/Screen_Shot_2014-10-17_at_15.44.03.png?1413557084"}},{"title":"SOCRATES-REDUCED: Vericiguat effect on NT-proBNP in patients with worsening HF may depend on dose","url":"http:\/\/ct.moreover.com\/?a=23311663423&p=1pl&v=1&x=_fC-D7lQJbkvcSNvBLn6nA","license":"public","citation_ids":[4738718],"posted_on":"2015-11-08T21:00:21+00:00","summary":"ORLANDO, Fla. \u2014 Vericiguat, a novel soluble guanylate cyclase stimulator, did not significantly influence changes in N-terminal pro-B-type natriuretic peptide in patients with worsening HF, according to findings presented at the American Heart\u2026","author":{"name":"Healio.com","url":"http:\/\/www.healio.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/968\/normal\/Screen_Shot_2015-04-10_at_13.36.33.png?1428669420"}},{"title":"Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure","url":"http:\/\/ct.moreover.com\/?a=23311069502&p=1pl&v=1&x=S5mxja0IZl0RRr0WEw1xZQ","license":"public","citation_ids":[4738718],"posted_on":"2015-11-08T05:00:00+00:00","summary":"Mihai Gheorghiade, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues randomly assigned 456 patients with worsening chronic HF and reduced left ventricular ejection fraction (a measure of how well the left\u2026","author":{"name":"EurekAlert!","url":"http:\/\/www.eurekalert.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/077\/normal\/image.png?1369859505"}}],"twitter":[{"url":"http:\/\/twitter.com\/JAMA_current\/statuses\/663460989535432704","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-08T21:00:01+00:00","author":{"name":"JAMA","url":"http:\/\/jama.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000143912285\/b018993d545bc3a951b018f2a1e24fb8_normal.png","description":"JAMA, published since 1883, is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMA_current","tweeter_id":"38489678","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":221269},"tweet_id":"663460989535432704"},{"url":"http:\/\/twitter.com\/HealMyHeartLA\/statuses\/663466036449181696","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-08T21:20:04+00:00","author":{"name":"Heal My Heart L.A.","url":"http:\/\/on.fb.me\/1IfO84g","image":"https:\/\/pbs.twimg.com\/profile_images\/728587343536500736\/Gzob_gnI_normal.jpg","description":"We promote health with a focus on cardiovascular disease and organ donation. #HealthySocialMedia. Follow or RTs are not endorsement.","id_on_source":"HealMyHeartLA","tweeter_id":"2453884124","geo":{"lt":null,"ln":null},"followers":5193},"tweet_id":"663466036449181696"},{"url":"http:\/\/twitter.com\/JAMACardio\/statuses\/663545230981918720","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-09T02:34:45+00:00","author":{"name":"JAMA Cardiology","url":"http:\/\/jamacardiology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/653584778738933760\/e3F5fsJa_normal.png","description":"JAMA Cardiology is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMACardio","tweeter_id":"3415715278","geo":{"lt":null,"ln":null},"followers":8101},"tweet_id":"663545230981918720"},{"url":"http:\/\/twitter.com\/swarsabelle\/statuses\/663703014717456384","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-09T13:01:44+00:00","author":{"name":"dolly \u265b","url":"http:\/\/kittie-cat.com","image":"https:\/\/pbs.twimg.com\/profile_images\/654111969193119745\/GFp1D_BX_normal.jpg","description":"MSI 4GB GeForce GTX 970 Intel i7 4790k Processor Corsair Vengeance 1600 MHz RAM (16GB) MSI Z97 Motherboard Corsair Carbide Series SPEC-02 Pink HyperX Cloud II","id_on_source":"swarsabelle","tweeter_id":"3920072596","geo":{"lt":"40.7305991","ln":"-73.9865812","country":"US"},"followers":102},"tweet_id":"663703014717456384"},{"url":"http:\/\/twitter.com\/medicineupdate\/statuses\/663728895980531713","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-09T14:44:34+00:00","author":{"name":"Tom","url":"http:\/\/j.gs\/1K3w","image":"https:\/\/pbs.twimg.com\/profile_images\/3388626222\/3c70af58befec0257424ebde88c5f261_normal.png","description":"The top 5 internal medicine journals","id_on_source":"medicineupdate","tweeter_id":"174988635","geo":{"lt":null,"ln":null},"followers":3332},"tweet_id":"663728895980531713"},{"url":"http:\/\/twitter.com\/CitelineJakeM\/statuses\/663738724363149312","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-09T15:23:38+00:00","author":{"name":"Jake Mathon","url":"http:\/\/www.citeline.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/701777660142350338\/O-rTTf4N_normal.jpg","description":"Principal Analyst - Cardiovascular & Metabolic\/Endocrinology. I'm also a Planning Commissioner, Cub Scout leader, & basketball coach. Views are mine.","id_on_source":"CitelineJakeM","tweeter_id":"2372312257","geo":{"lt":44.43755,"ln":-73.06818,"country":"US"},"followers":196},"tweet_id":"663738724363149312"},{"url":"http:\/\/twitter.com\/gerrit_brand\/statuses\/664024555300790272","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-10T10:19:25+00:00","author":{"name":"Gerrit Brand","image":"https:\/\/pbs.twimg.com\/profile_images\/2411216675\/bart_parker_portrait_1968_normal.jpg","description":"Medicine. Technology. Future. Architecture. Food. Politics. Life. Desert. Currently working in psychiatric care. Twitter is CME.","id_on_source":"gerrit_brand","tweeter_id":"704400456","geo":{"lt":52.5,"ln":13.41667,"country":"DE"},"followers":832},"tweet_id":"664024555300790272"},{"url":"http:\/\/twitter.com\/AMAManual\/statuses\/664117546887565312","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-10T16:28:56+00:00","author":{"name":"AMA Manual of Style","url":"http:\/\/www.amamanualofstyle.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3055819016\/6615c86fb9eda227630123ac48895aa7_normal.jpeg","description":"Everything you need to produce well-organized, clear, and readable manuscripts.","id_on_source":"AMAManual","tweeter_id":"224703237","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":5070},"tweet_id":"664117546887565312"},{"url":"http:\/\/twitter.com\/JAMA_current\/statuses\/664160059274956801","license":"gnip","rt":["AMAManual"],"citation_ids":[4738718],"posted_on":"2015-11-10T19:17:52+00:00","author":{"name":"JAMA","url":"http:\/\/jama.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000143912285\/b018993d545bc3a951b018f2a1e24fb8_normal.png","description":"JAMA, published since 1883, is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMA_current","tweeter_id":"38489678","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":221269},"tweet_id":"664160059274956801"},{"url":"http:\/\/twitter.com\/JAMACardio\/statuses\/664546196204216320","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T20:52:14+00:00","author":{"name":"JAMA Cardiology","url":"http:\/\/jamacardiology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/653584778738933760\/e3F5fsJa_normal.png","description":"JAMA Cardiology is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMACardio","tweeter_id":"3415715278","geo":{"lt":null,"ln":null},"followers":8101},"tweet_id":"664546196204216320"},{"url":"http:\/\/twitter.com\/acafarmur\/statuses\/664493425694232576","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-11T17:22:33+00:00","author":{"name":"ACAFARMUR","url":"http:\/\/www.academiadefarmaciaregiondemurcia.com","image":"https:\/\/pbs.twimg.com\/profile_images\/417020675857981440\/dV0DUx1E_normal.jpeg","description":"Academia de Farmacia Sta. M\u00aa de Espa\u00f1a de la Regi\u00f3n de Murcia","id_on_source":"acafarmur","tweeter_id":"2266321460","geo":{"lt":null,"ln":null},"followers":524},"tweet_id":"664493425694232576"},{"url":"http:\/\/twitter.com\/DitchDocRN14\/statuses\/664494774519521281","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:27:54+00:00","author":{"name":"Steph","image":"https:\/\/pbs.twimg.com\/profile_images\/2455378515\/image_normal.jpg","description":"An old-school DitchDoc, PHRN, MSN-FNP sharing articles, thoughts & recipes 4 my fellow warriors. Dig in &get dirty.#Paramedic #FOAMed #FOAMems#FOANed #softball","id_on_source":"DitchDocRN14","tweeter_id":"324912759","geo":{"lt":null,"ln":null},"followers":855},"tweet_id":"664494774519521281"},{"url":"http:\/\/twitter.com\/chemafraile\/statuses\/664495244927479808","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:29:46+00:00","author":{"name":"Jose Maria Fraile","image":"https:\/\/pbs.twimg.com\/profile_images\/619998776376336384\/kxCNn6vl_normal.jpg","description":"MD, Palliative Medicine.\nMadrid. Spain.","id_on_source":"chemafraile","tweeter_id":"230702814","geo":{"lt":null,"ln":null},"followers":131},"tweet_id":"664495244927479808"},{"url":"http:\/\/twitter.com\/catambuco\/statuses\/664496097797255168","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:33:10+00:00","author":{"name":"R DiazdelCastillo N.","url":"http:\/\/www.scc.org.co","image":"https:\/\/pbs.twimg.com\/profile_images\/909556507586568192\/KkqfKuUh_normal.jpg","description":"R.D\u00edaz del Castillo N. MD FACC FSIAC\nM\u00e9dico Cirujano Cardiovascular Surgeon.La Pitie, Mondor, Foch.\nPastpresident de la Sociedad Sudamericana de Cardiologia","id_on_source":"catambuco","tweeter_id":"127682706","geo":{"lt":null,"ln":null},"followers":1117},"tweet_id":"664496097797255168"},{"url":"http:\/\/twitter.com\/TheKancerFound\/statuses\/664505263131656192","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T18:09:35+00:00","author":{"name":"Kancer Foundation","url":"http:\/\/thekancerfoundation.com","image":"https:\/\/pbs.twimg.com\/profile_images\/587449254911807491\/PrZ-Qcga_normal.jpg","description":"The Official Twitter Account of The Kancer Foundation.","id_on_source":"TheKancerFound","tweeter_id":"3126476398","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":1141},"tweet_id":"664505263131656192"},{"url":"http:\/\/twitter.com\/JAMA_current\/statuses\/664487756366815232","license":"gnip","citation_ids":[4738718],"posted_on":"2015-11-11T17:00:01+00:00","author":{"name":"JAMA","url":"http:\/\/jama.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000143912285\/b018993d545bc3a951b018f2a1e24fb8_normal.png","description":"JAMA, published since 1883, is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMA_current","tweeter_id":"38489678","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":221269},"tweet_id":"664487756366815232"},{"url":"http:\/\/twitter.com\/ernestocardio\/statuses\/664489583355281408","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:07:16+00:00","author":{"name":"Ernesto Rodr\u00edguez H","image":"https:\/\/pbs.twimg.com\/profile_images\/836419510760574976\/SDz-He7__normal.jpg","description":"VENEZOLANO.CARDIOLOGO Egresado de ULA. Cardiac CT. Member of SVC-SEC Y ESC . Member of Red Sox Nation . Fan Number One Of Boston Red Sox.","id_on_source":"ernestocardio","tweeter_id":"79594985","geo":{"lt":8,"ln":-66,"country":"VE"},"followers":801},"tweet_id":"664489583355281408"},{"url":"http:\/\/twitter.com\/medvox\/statuses\/664491438034546688","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:14:39+00:00","author":{"name":"Fernando Schifferli","url":"http:\/\/www.lulu.com\/product\/item\/el-martillo-de-agua\/18926639","image":"https:\/\/pbs.twimg.com\/profile_images\/1866192026\/Antart_normal.jpg","description":"M\u00e9dico (MD) - Periodista (Journalist). Universidad de Santiago de Chile (USACH).\r\nAmague de escritor (draft writer). Pseud\u00f3nimo: Acir Emadus.-","id_on_source":"medvox","tweeter_id":"19041530","geo":{"lt":-30,"ln":-71,"country":"CL"},"followers":367},"tweet_id":"664491438034546688"},{"url":"http:\/\/twitter.com\/rabonaldi\/statuses\/664491449971548160","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-11-11T17:14:41+00:00","author":{"name":"Roberto Bonaldi","image":"https:\/\/pbs.twimg.com\/profile_images\/825169563729948672\/VWnxPhzl_normal.jpg","id_on_source":"rabonaldi","tweeter_id":"2955424079","geo":{"lt":null,"ln":null},"followers":453},"tweet_id":"664491449971548160"},{"url":"http:\/\/twitter.com\/annalsthorsurg\/statuses\/672173407929110528","license":"gnip","rt":["AMAManual"],"citation_ids":[4738718],"posted_on":"2015-12-02T22:00:03+00:00","author":{"name":"AnnalsofThorSurg","url":"http:\/\/annalsthoracicsurgery.org","image":"https:\/\/pbs.twimg.com\/profile_images\/910251578816425985\/6GOqvSx__normal.jpg","description":"__The Annals of Thoracic Surgery__         Official Journal of The Society of Thoracic Surgeons and The Southern Thoracic Surgical Association","id_on_source":"annalsthorsurg","tweeter_id":"3064547301","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":1871},"tweet_id":"672173407929110528"},{"url":"http:\/\/twitter.com\/CardioPharmUK\/statuses\/672525306377445376","license":"gnip","citation_ids":[4738718],"posted_on":"2015-12-03T21:18:22+00:00","author":{"name":"Helen Williams","image":"https:\/\/pbs.twimg.com\/profile_images\/487905423157387264\/D5AcFeZB_normal.jpeg","description":"Pharmacist and cardiovascular specialist","id_on_source":"CardioPharmUK","tweeter_id":"2702683761","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":608},"tweet_id":"672525306377445376"},{"url":"http:\/\/twitter.com\/JavaClinical\/statuses\/673872110595518464","license":"gnip","citation_ids":[4738718],"posted_on":"2015-12-07T14:30:05+00:00","author":{"name":"Java Clinical","url":"http:\/\/www.javacr.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3090580003\/76cadb612ea8829abe8c3f2147e66494_normal.png","description":"Java Clinical Research is a full service CRO providing complete clinical trial management to the pharma, biotech and medical device industries.","id_on_source":"JavaClinical","tweeter_id":"498895068","geo":{"lt":53.33306,"ln":-6.24889,"country":"IE"},"followers":338},"tweet_id":"673872110595518464"},{"url":"http:\/\/twitter.com\/JAMA_current\/statuses\/673924938307387393","license":"gnip","citation_ids":[4738718],"posted_on":"2015-12-07T18:00:00+00:00","author":{"name":"JAMA","url":"http:\/\/jama.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000143912285\/b018993d545bc3a951b018f2a1e24fb8_normal.png","description":"JAMA, published since 1883, is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMA_current","tweeter_id":"38489678","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":221269},"tweet_id":"673924938307387393"},{"url":"http:\/\/twitter.com\/JAMACardio\/statuses\/674246036739784704","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-12-08T15:15:56+00:00","author":{"name":"JAMA Cardiology","url":"http:\/\/jamacardiology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/653584778738933760\/e3F5fsJa_normal.png","description":"JAMA Cardiology is an international, peer-reviewed medical journal published weekly.","id_on_source":"JAMACardio","tweeter_id":"3415715278","geo":{"lt":null,"ln":null},"followers":8101},"tweet_id":"674246036739784704"},{"url":"http:\/\/twitter.com\/L_Borgese\/statuses\/674291624860590080","license":"gnip","rt":["JAMA_current"],"citation_ids":[4738718],"posted_on":"2015-12-08T18:17:05+00:00","author":{"name":"Laura Borgese","image":"https:\/\/pbs.twimg.com\/profile_images\/782471331099074560\/kzo-1oZV_normal.jpg","description":"Biotech, Med Student but above all Researcher Inside","id_on_source":"L_Borgese","tweeter_id":"3930553048","geo":{"lt":null,"ln":null},"followers":27},"tweet_id":"674291624860590080"},{"url":"http:\/\/twitter.com\/medicineupdate\/statuses\/684416580432756740","license":"gnip","citation_ids":[4738718],"posted_on":"2016-01-05T16:50:03+00:00","author":{"name":"Tom","url":"http:\/\/j.gs\/1K3w","image":"https:\/\/pbs.twimg.com\/profile_images\/3388626222\/3c70af58befec0257424ebde88c5f261_normal.png","description":"The top 5 internal medicine journals","id_on_source":"medicineupdate","tweeter_id":"174988635","geo":{"lt":null,"ln":null},"followers":3332},"tweet_id":"684416580432756740"}],"blogs":[{"title":"Richard Lehman\u2019s journal review\u20147 December","url":"http:\/\/blogs.bmj.com\/bmj\/2015\/12\/07\/richard-lehmans-journal-review-7-december\/","license":"public","citation_ids":[4744812,4592518,4831350,4837632,4828113,4738718,4828120,4742253,4742310,4742309,4834583,4833472,4836563],"posted_on":"2015-12-07T12:00:00+00:00","summary":"NEJM 3 Dec 2015 Vol 373CPR with or without breaks\n2203 Cardiopulmonary resuscitation for cardiac arrest outside hospital carries a mortality risk of more than 90%. It is usually assumed that the death rate would otherwise be 100%, but trials of CPR don&rsq","author":{"name":"Latest BMJ blogs","url":"http:\/\/blogs.bmj.com\/bmj","description":"Just another blogs.bmj.com weblog"}}],"facebook":[{"title":"Timeline Photos","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10153248850558341&id=87087958340","license":"public","citation_ids":[4738718],"posted_on":"2015-12-07T18:00:01+00:00","summary":"Phase 2 study investigates the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic heart failure with reduced left ventricular ejection fraction. http:\/\/ja.ma\/1QPtGLg","author":{"name":"JAMA","url":"https:\/\/www.facebook.com\/87087958340","facebook_wall_name":"JAMA, Journal of the American Medical Association","image":"https:\/\/graph.facebook.com\/87087958340\/picture","id_on_source":"87087958340"}},{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10153207264043341&id=87087958340","license":"public","citation_ids":[4738718],"posted_on":"2015-11-11T17:00:01+00:00","summary":"Among patients with worsening chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF), compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerate","author":{"name":"JAMA","url":"https:\/\/www.facebook.com\/87087958340","facebook_wall_name":"JAMA, Journal of the American Medical Association","image":"https:\/\/graph.facebook.com\/87087958340\/picture","id_on_source":"87087958340"}},{"title":"Timeline Photos","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10153202954483341&id=87087958340","license":"public","citation_ids":[4738718],"posted_on":"2015-11-08T21:00:02+00:00","summary":"This article is published online first to coincide with presentation at the American Heart Association Scientific Sessions 2015.\n\nThis phase 2 study investigates the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in pa","author":{"name":"JAMA","url":"https:\/\/www.facebook.com\/87087958340","facebook_wall_name":"JAMA, Journal of the American Medical Association","image":"https:\/\/graph.facebook.com\/87087958340\/picture","id_on_source":"87087958340"}},{"title":"JAMA","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1681360145443695&id=1648414928738217","license":"public","citation_ids":[4738718],"posted_on":"2015-12-07T19:27:00+00:00","summary":"Phase 2 study investigates the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic heart failure with reduced left ventricular ejection fraction. http:\/\/ja.ma\/1QPtGLg","author":{"name":"JAMA Cardiology","url":"https:\/\/www.facebook.com\/1648414928738217","facebook_wall_name":"JAMA Cardiology","image":"https:\/\/graph.facebook.com\/1648414928738217\/picture","id_on_source":"1648414928738217"}},{"title":"JAMA","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1674202606159449&id=1648414928738217","license":"public","citation_ids":[4738718],"posted_on":"2015-11-11T17:15:20+00:00","summary":"Among patients with worsening chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF), compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerate","author":{"name":"JAMA Cardiology","url":"https:\/\/www.facebook.com\/1648414928738217","facebook_wall_name":"JAMA Cardiology","image":"https:\/\/graph.facebook.com\/1648414928738217\/picture","id_on_source":"1648414928738217"}},{"title":"JAMA","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1673493296230380&id=1648414928738217","license":"public","citation_ids":[4738718],"posted_on":"2015-11-09T02:33:18+00:00","summary":"This article is published online first to coincide with presentation at the American Heart Association Scientific Sessions 2015.\n\nThis phase 2 study investigates the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in pa","author":{"name":"JAMA Cardiology","url":"https:\/\/www.facebook.com\/1648414928738217","facebook_wall_name":"JAMA Cardiology","image":"https:\/\/graph.facebook.com\/1648414928738217\/picture","id_on_source":"1648414928738217"}}]}}